In recent years, different drugs have appeared that have been successful among consumers. If a few months ago we talked about a new, powerful and deadly substance known as Flakka, in today’s article we are going to review the characteristics of a new drug called Tucibi (in English, 2CB) which has become fashionable for its hallucinogenic effects.
The Tucibi It is a psychedelic substance that, according to those who have tried it, alters all the senses The person experiences visual and thought hallucinations, where the power of the imagination is magnified, and can cause a terrible state of panic. Like many phenylethylamines (PEA), the person notices a very pleasant high for the body itself, a sensation of exaggerated strength and intense nervousness and excitement. It is known as the new drug of the rich due to its high price.
Tucibi is a designer drug. These types of drugs were born between 1970 and 1980 in hundreds of clandestine laboratories in the United States, since during that time, in the North American country, the sale of hallucinogens was prohibited. In clandestine laboratories, chemical compounds similar in structure and effect to prohibited drugs began to be synthesized. Designer drugs are obtained through chemical processes of greater or lesser complexity. Evidently, The objective of traffickers of designer drugs is to make business and escape coercive controls
At that time, when a new synthetic drug was discovered, the North American authorities included them on the lists of prohibited substances. In 1987, when the US government amended the Controlled Substance Act, any substance similar to a banned substance also began to be considered prohibited. Later, the World Health Organization adopted the same decision, giving it international validity.
The Tucibi (also called Venus) belongs to the third group of designer drugs.
2CB Features
Tucibi (2C-B) or 4-bromo-2,5-dimethoxyphenylethylamine (also called: a-desmethyl-DOB, BDMPEA, MFT, Erox, Venus, Nexus) is a psychedelic phenylethylamine of the 2C family. It was first synthesized by Alexander Shulgin in 1974. The dosage varies between 16 and 24 mg, and It is usually consumed in powder form (presented with bags in which printed figures appear, for example, colored drawings, the S of Superman, skulls, etc.), although it can also be consumed in pills or capsules.
The effects of this substance combine those of two other well-known designer drugs: MDMA and LSD. Still, its hallucinogenic effects are not as potent as those of LSD, and the stimulants are not as intense as those of MDMA. At low doses the stimulant effects predominate, while at high doses the psychedelic effects become more noticeable. The effects usually last between 4 and 8 hours.
Risks associated with its consumption
Like any drug, Tucibi can produce serious effects on the health of the person who consumes it In addition to the problems that may arise in their social environment and daily life, such as loss of employment or family problems. Consumption of 2CB can cause problems both in the short and long term. In the short term, it is characteristic that many users, due to the hallucinations produced by this substance, suffer panic attacks or anxiety attacks.
In the long term, continued use of this drug It is associated with serious problems of anxiety, disorientation and extreme fatigue Regular users often end up suffering from a depressive process and. In severe cases, they may suffer from psychotic disorders (such as schizophrenia or paranoid disorder) and depersonalization.
The consumption of Tucibi is also a reality in Spain. On June 18, 2016, Spanish police arrested nine people on charges of illegal trafficking of this substance after a raid on a clandestine laboratory located in Madrid.
Eight of the nine detainees are Colombian citizens, as confirmed by police authorities. In addition to Tucibi, the agents found a large amount of cocaine, methamphetamine and ketamine in their searches of two apartments and the clandestine laboratory of the detainees.
Moya, PR; Berg, K.A.; Gutiérrez-Hernández, MA; Sáez-Briones, P.; Reyes-Parada, M.; Cassels, B.K.; Clarke, W. P. (2007). “Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors.” The Journal of pharmacology and experimental therapeutics 321 (3).
Villalobos CA; Bull P.; Sáez, P.; Cassels, B.K.; Huidobro-Toro, JP (2004). “4-Bromo-2,5-dimethoxyphenethylamine (2C-B) and structurally related phenylethylamines are potent 5-HT2A receptor antagonists in Xenopus laevis oocytes.” British Journal of Pharmacology 141 (7): 1167-74.
